Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 108   

Articles published

NVS 84.67 +0.26 (0.31%)
price chart
Traders Recap - Novartis AG (ADR)(NYSE:NVS), Zions Bancorporation ...
Novartis AG (ADR) (NYSE:NVS) opened the session at $81.77, trading in a range of $80.77 to $81.90, and closed at $81.30.
Related articles »  
Stocks in the Spotlight - Novartis AG (ADR) (NYSE:NVS), China Petroleum ...
Novartis AG (ADR) (NYSE:NVS) opened the session at $81.77, trading in a range of $80.77 to $81.90, and closed at $81.30.
Top News: Roche Holding (OTCMKTS:RHHBY), Novartis (NYSE:NVS), Goldcorp ...
Novartis AG (ADR) (NYSE:NVS) needs to continue investing in research in order to develop new drugs that national health-care systems are willing pay for, a task that gets harder as generic versions of older medicines become available, according to the ...
News Buzzer: Novartis (NYSE:NVS), Shanda Games (NASDAQ:GAME), Darden ...  eMarketsDaily
Related articles »  
ADR Shares End Mostly Higher; Toyota Shares Active
International stocks trading in New York closed mostly higher on Wednesday, with the Bank of New York index of American depositary receipts adding 1.1% to 152.86.
ADR Shares End Lower; Vodafone Shares Active
Swiss drug maker Novartis AG (NVS, NOVN.VX) shuffled its top management in Japan and froze funding to doctor-led clinical trials in the country, in an effort to redeem a reputation tarnished by admissions of misconduct in its second-largest market ...
Related articles »  
ADR Shares End Higher; America Movil Shares Active
A Food and Drug Administration staff review recommended against approving Novartis AG's (NVS, NOVN.VX) heart-failure drug serelaxin because the data didn't show it slowed progress of heart failure nor did it "provide persuasive evidence of an effect ...
Related articles »  
Investor's Digest: Sunoco Logistics Partners LP (NYSE:SXL), VAALCO Energy ...
Having noted that its experimental heart failure drug LCZ696 showed significant success in patients, Novartis AG (ADR) (NYSE:NVS) is now seeking early approval of the drug. Approval of the drug will effectively boost the company's portfolio in cardiac ...
Related articles »  
Pfizer Inc. (NYSE:PFE): Potential New Oncology Therapy
Pfizer Inc. (NYSE:PFE) is in the lead at this point to bring this new class of CDK 4/6 inhibitor drugs to the market but competitors - Novartis AG (ADR) (NYSE:NVS) and Eli Lilly and Co (NYSE:LLY) - are testing their own drugs. Other Drugs. With its ...
Stocks to Watch - AngioDynamics, Inc. (NASDAQ:ANGO), Lennar Corporation ...
In the preceding trading session, Novartis AG (ADR) (NYSE:NVS) exchanged 1.13 million shares and the average volume remained 1.94 million shares.
ADR Shares End Higher; Noah Education Shares Active
A third-party probe into the Japanese unit of Swiss drug giant Novartis AG (NVS, NOVN.VX) said its staff tried to cover up evidence and were involved in a number of questionable activities, but concluded that data wasn't falsified in clinical research ...
Related articles »